Allosite Therapeutics

Allosite Therapeutics is a biotechnology company and a subsidiary of BridgeBio Pharma focused on the discovery and development of allosteric small molecule inhibitors for oncology. The company leverages a proprietary platform to identify and target allosteric sites on proteins that are traditionally difficult to inhibit through orthosteric means. Its lead program, BBP-126, is a potent and selective allosteric inhibitor of AKT, a key node in the PI3K/AKT/mTOR signaling pathway that is frequently dysregulated in various cancers. By targeting the inactive conformation of the kinase, Allosite aims to achieve superior isoform selectivity and a reduced toxicity profile compared to conventional catalytic site inhibitors. The company was integrated into BridgeBio's hub-and-spoke model to accelerate the clinical development of its precision medicine candidates.